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Bioinformatics is the application of omics science, information technology, mathematics and statistics in the field of
biomarker detection. Clinical bioinformatics can be applied for identification and validation of new biomarkers to
improve current methods of monitoring disease activity and identify new therapeutic targets. Acute lung injurt
(ALI)/Acute respiratory distress syndrome (ARDS) affects a large number of patients with a poor prognosis. The
present review mainly focused on the progress in understanding disease heterogeneity through the use of evolving
biological, genomic, and genetic approaches and the role of clinical bioinformatics in the pathogenesis and
treatment of ALI/ARDS. The remarkable advances in clinical bioinformatics can be a new way for understanding
disease pathogenesis, diagnosis and treatment.
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Introduction
In recent years, there is a great increase in genomics and
other molecular research which produced a tremendous
amount of information related to molecular biology
[1-3]. Meantime, various powerful data mining and stat-
istical bioinformatics methods have been propagated
for identifying, prioritizing and classifying robust and
generalizable biomarkers with high discriminatory ability
[4], and some online bioinformatics data libraries, such
as Enzyme, KEGG, Gene Ontology, NCBI Taxonomy,
SwissProt and TrEMBL were generated for the store and
management of data. Bioinformatics now entails the cre-
ation and advancement of databases, algorithms, compu-
tational and statistical techniques and theory to solve
formal and practical problems arising from the manage-
ment and analysis of biological data.
Clinical bioinformatics is a new emerging science
combining clinical information, (including patients’ com-
plaints, history, clinical symptoms and signs, physicians’
examinations, biochemical analysis, imaging profiles,* Correspondence: Xiangdong.wang@telia.com
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in any medium, provided the original work is ppathologies), omics science, mathematics, information
technology and library data together. It may play a
potentially important role in the discovery of biomar-
kers, which will facilitate the diagnosis of disease, as well
as treatment. A commonly used definition of a bio-
marker is “a characteristic that is objectively measured and
evaluated as an indicator of normal biological process,
pathogenic processes, or pharmacologic responses to a
therapeutic intervention” [5]. Clinical bioinformatics is
also a new way to focus on the combination of clinical
symptoms and signs with human tissue-generated bio-
informatics to get deep and full understand of the risk
factors, pathogenesis and progress of human disease.
Recent technological developments in genomics, proteo-
mics, metabolomics, are allowing researchers to take an
unbiased ‘big-picture’ approach to further elucidate the
molecular pathogenesis of lung injury [6] (Figure 1).
Recent years, clinical bioinformatics have been widely
applied in the investigation of various kinds of diseases
including acute lung injury.
Acute lung injury (ALI)/acute respiratory distress syn-
drome (ARDS) remains a major cause of high morbidity,
mortality, and health care costs in critically ill patients
[7]. ALI/ARDS is an acute life-threatening form of
hypoxemic respiratory failure, characterized by lung tis-
sue edema and injury, inflammatory responses, and com-
promised gas exchange following macrophage activation,Open Access article distributed under the terms of the Creative Commons


















Figure 1 The optimum pattern of clinical bioinformatics in ALI/ARDS. We get clinical information including symptoms, physical signs,
medical history, lung function or images from the patients. On the other hand, we draw bioinformation from their blood, BALF or tissue. Then,
the clinical information and bioinformation should be validated and complemented with each other in order to detect effective and powerful
biomarkers. Only in this way, the bioinformatics technologies can be helpful.
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matory cells could be activated to produce a large num-
ber of mediators in the early stage of the disease,
resulting in injury to both the vascular endothelium and
the alveolar epithelium [8,9]. Injury to the alveolar-
capillary barrier increases permeability of the alveolar
wall, increases accumulation of inflammatory cells and
cytokines, and impairs alveolar fluid clearance, resulting
in accumulation of protein-rich edema in the alveolar
space [9].
The incidence of ALI/ARDS was reported to be 80 per
100,000 person-years with a mortality rate of 40% in
United States [10]. A prospective study conducted in
Chinese pediatric intensive care units indicated that the
incidence of ARDS in critically ill patients was 2.7% with
a mortality rate of 44.8% [11]. The reported incidence of
pediatric ARDS in US was about 9.5% [12], with the
overall mortality rate of 22% [13]. Over the past two
decades, a variety of interventions and intensive care
strategies have been used in treating patients with ALI/
ARDS. However, only low tidal volume ventilationaccompanied with fluid management has been shown to
be beneficial in improving morbidity and mortality [14].
There is an urgent need to identify and validate disease-
specific biomarkers and novel therapeutic strategies for
ALI/ARDS.
Application of bioinformatics in ALI/ARDS
Genomics study in ALI is an approach to detect asso-
ciated genetic variations, or gene polymorphisms, which
may contribute to ALI susceptibility, severity or progno-
sis in a racial- and ethnic-specific manner. Examples of
this approach include microarray based genome-wide
expression analyses [15] and genotype detection for spe-
cific gene [16]. Although genome-wide expression profil-
ing is an excellent method for generating long lists of
candidates, it is proving to be more difficult to develop
follow-on approaches to select critical genes. Then, if
specific gene is supposed to be involved in the pathogen-
esis of ALI/ARDS, genotyping by PCR or sequencing
can be applied to validate the significance of those sus-
pected genes. Proteomics captures a comprehensive set
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biological function of cells or organs [17-19]. Commonly
used methods for current proteomics studies include
two-dimensional gel electrophoresis (2-DE) followed by
matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF MS), liquid chroma-
tography coupled to electrospray ionization tandem MS
(LC-ESI MS/MS), surface-enhanced laser desorption/
ionization coupled to TOF MS (SELDI-TOF MS), capil-
lary electrophoresis coupled to MS, and microarrays
[19]. In the pulmonary proteomic studies, bronchoalveo-
lar lavage fluid (BALF), lung tissue, blood and alveolar
cells have been used extensively.
The collection of global metabolic data and their inter-
pretation (both spectral and biochemical) with modern
spectroscopic techniques and appropriate statistical
approaches is called “metabolic profiling” or “metabo-
lomics” [20-22]. It is an emerging component of the
systems biology approach for the discovery of clinically
relevant biomarkers and potential therapeutic targets
[23]. The most often applied technology is nuclear mag-
netic resonance (NMR) and mass spectrometry [24-26].
Since NMR spectrometry can identify and quantify mul-
tiple metabolites from a single liquid or solid sample
and it’s cost effective and robust, it proved to be very
useful in metabolomics studies.
Biomarker development in ALI/ARDS
Genomics
There are several publications reviewed the application
of genomics in the study of ALI. In 2002, Marshall and
his colleagues provide the first evidence of a genetic
influence in ARDS, suggesting an important role for
angiotensin converting enzyme (ACE) [16]. In this study,
a total of 358 patients were enrolled including 96
patients fulfilling American/European Consensus Com-
mittee criteria for ARDS, 174 coronary artery bypass
graft (CABG) controls and 88 non-ARDS but require
mechanical ventilation patients in the intensive care unit
(ICU). DNA was extracted from whole blood samples
and ACE genotype was determined by three-primer
polymerase chain reaction amplification. This study
detected that the frequency of the DD genotype and the
D allele was markedly increased in patients with ARDS
compared with both the CABG and ICU comparison
groups and the healthy population sample [16].
Similarly, Gong, et al demonstrated that -308GA pro-
moter polymorphism in the TNF-a gene was associated
with the mortality of ARDS [27]. SNPs of 43 Toll like
receptor-related genes were identified and one of these
genes was demonstrated to be associated with suscepti-
bility to organ dysfunction and death in patients with sep-
sis [28]. Later, pre–B-cell colony-enhancing factor (PBEF)
was found significantly increased in the expressionprofiling in animal models of ALI and in human ALI.
In this study, multiple technologies including PCR, micro-
array analysis and some proteomic measurement methods
were used. This combination of various technologies in
bioinformatics study is important and helpful [29].
However, different from these traditional epidemio-
logical studies in at risk populations, Marzec.et al first
applied positional cloning and gene sequencing to iden-
tify candidate susceptibility genes and SNP polymorph-
ism. They demonstrated that the -617 A SNP of Nrf2
(NF-E2 related factor 2) had a significantly higher risk
for developing ALI after major trauma [30]. Then a
large-scale candidate gene genotypings were carried out
in a cohort of critically ill subjects with trauma to iden-
tify ALI risk variants after major trauma. Five SNPs were
found to have a significant association with ALI, of
which two SNPs in ANGPT2 (rs1868554 and rs2442598)
replicated the significant association with ALI. And fur-
thermore, the top associated SNPs were tested in a mul-
ticenter case-control population [31]. In a two-stage
discovery/validation study, the commonly occurring FAS
haplotype including FAS21541T and FAS9325A was sig-
nificantly associated with ALI susceptibility and increased
FAS mRNA expression in peripheral leukocytes in
response to innate immune stimulation [32]. A complete
summary of all published applications of genetics in the
study of ALI/ARDS is far beyond the scope of this review.
Table 1 provides a summary, with references, of some of
the most recently or interesting applications of genetics in
the diagnosis, susceptibility or prognosis of ALI/ARDS
[31-37].
Among these identified genes, some of them were well
demonstrated to play critical roles in the development of
ALI/ARDS. NADPH oxidase contributed to the produc-
tion of reactive oxygen species, which is able to induce a
cell death response in oxidative stress. NADPH oxidase
1 was reported to act as an important mediator of acute
lung injury mediated by oxidative stress, particularly in
alveolar cells. NOX1-generated ROS are largely respon-
sible for alveolar cell death and subsequent lung injury
through JNK and ERK pathways [38]. Angiopoietin-2
(ANGPT2) has been implicated in pulmonary vascular
leak syndromes including ALI and sepsis in both animal
and human studies [39,40], while recently, two ANGPT2
SNPs (rs2442598 and rs1868554) were found to be
strongly associated with the development of ALI in
patients with major trauma [31]. However, studies are
warranted to further elucidate the characterization of
ANGPT2 genetic variation and expression. Fas pathway
has been investigated as a potential contributor to the
inflammation and alveolar epithelial cell apoptosis
observed in the lungs of patients with ALI [41,42]. SP-B
enhances the rate of phospholipid absorption to the
alveolar air/water interface [43], decreases surface
Table 1 Examples of application for genetics in the pathogenisis of ALI in 2011
Genes Technologies Relationship with ALI Ref.
NADPH oxidase NOX2 subunit knockout mice NOX-2(-/-) mice exhibited diminished TNF
alpha-induced acute inflammatory responses
in the lungs but not other tissues, as evidenced
by decreased activation of the redox-sensitive
transcription factor NF-kappa B, and decreased
gene expression of IL-1 beta, IL-6, TNF alpha,
E-selectin, and other cellular adhesion molecules.
[33]
ANGPT SNP array performed in ALI and non-ALI
patients
An ANGPT2 region is associated with both ALI
and variation in plasma angiopoietin-2 isoforms.
[31]
Fas (CD95) Genptyped 14 SNPs in FAS in healthy white
volunteers and patients with ALI
Common genetic variants in FAS are associated
with ALI susceptibility
[32]
Surfactant protein B (SPB) Genotyping was performed on seven linkage
isequilibrium-tag SNP in the surfactant
protein B gene
SPB are associated with more severe lung injury
as indicated by the association of specific SNP
genotypes and haplotypes with the need for
mechanical ventilation in African American children
with community-acquired pneumonia.
[34]
Acvr1, Arhgap15, Cacnb4, Cacybp,
Ccdc148,Fancl, Mycn, Mgat4a, Rfwd2,
Tgfbr3, and Tnn
haplotype association mapping, microarray/
qRT-PCR analyses, in silico SNP
11 candidate genes are associated with acrolein-
induced acute lung injury in 40 different inbred
strains of mice
[35]
IRAKs tagging SNPs array common SNPs in IRAK3 gene might be
determinants for sepsis-induced ALI. association
with ALI development among septic patients
[36]
nmMLCK nmMLCK knockout mice,
nmMLCK silencing RNA
nmMLCK knockout mice were significantly protected
from VILI,
[37]
Abbreviations: Ref:Reference; ANGPT:angiopoietin; NADPH:glyceraldehyde-3-phosphate dehydrogenase; NOX:NADPH oxidases; TNF-alpha:tumor necrosis factor
alpha; IL-1:interleukin-1; IL-6:interleukin-6; SPB:Surfactant protein B; Acvr1: activin A receptor, type 1; ARHGAP15:Rho GTPase activating protein 15; CACNB4:calcium
channel, voltage-dependent, β 4 subunit; CACYBP:calcyclin binding protein; CCDC148:coiled-coil domain containing 148; FANCL: Fanconi anemia, complementation
group L; MYCN:v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian); MGAT4A: mannoside acetylglucosaminyltransferase 4, isoenzyme A;
RBMSl:RNA binding motif, single stranded interacting protein 1; RFWD2:Ring finger and WD repeat domain 2; TGFBR3:transforming growth factor-β receptor III;
TNN: tenascin N; IRAKs: interleukin-1 receptor-associated kinase genes; nmMLCK: non-muscle myosin light chain kinase isoform; VILI:ventilator induced lung injury.
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between water molecules [44] and has anti-inflammatory
properties [45]. However, the others were seldom
reported and futher studies are needed to validate their
functions in ALI/ARDS.
Gene expression profiles represent only a small frac-
tion of the complexity in an organism. On the other
hand, gene expression data obtained by the microarray
analysis are usually moderately correlated with the
expression levels of corresponding protein products due to
the post-transcriptional regulation. Thus, extrapolation of
protein expression on the basis of microarray-based gene
expression measurements must be validated by direct
measurement of the protein [15]. Then proteomics comes.
Proteomics
Proteomics captures a nearly comprehensive set of
expressed proteins in a cell or organism, which deter-
mine how a cell or organism functions. Proteomics
become more practical and feasible for researchers in
the field of pulmonary medicine using BALF, lung tissue,
and exhaled breath condensates as the source of protein
analysis [46]. In 2003, Bowler et al first applied the
proteomic approach in the BALF, plasma and lung
edema fluid in ALI/ARDS. In this paper, the authorreported that although many of the proteins were
demonstrated to have increased or decreased relative
intensity in the plasma and EF of ALI patients compared
with normal subjects, a limitation to the 2-DE proteo-
mics approach is that it is not easy to quantify all
changes in relative protein expression among a large
number of samples. The author mentioned that the pro-
teomics approach may be complementary to microarray
studies [47].
Shotgun proteomics in BALF was analyzed and 870
different proteins were identified, including surfactant,
proteases, and serum proteins. However, because of the
several limitations of the 2DE method to detect particu-
lar classes of proteins [48], it can only be treated as an
excellent screening tool to initially characterize a sample
of mostly unknown protein composition, and additional
methods, including isolation of subpopulations of pro-
teins and further refinement of the methodologies must
be cooperated to identify specific proteins [49]. Then,
through the combined application of SELDI-TOF, 2-DE
and western blot analysis, apolipoprotein A1, and S100
calcium-binding proteins A8 and A9 were detected to
increase in the inflammatory BALF [50].
Following these studies, quantitative proteomic ana-
lysis was then used to profile the changes in protein
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course of acute lung injury. Computational analysis as
used to map complex protein interactions in the lung
fluids and study how these interactions changed during
the course of ARDS. This approach to protein network
analysis identified novel mediators of acute lung injury
and protein pathways were redundant and involved in
multiple biological processes [51].
Table 2 provides a summary of the proteomic study in
ALI/ARDS from 2009-2011 [52-58]. Caveolin-1 is
involved in PMN adhesion, chemotaxis, and epithelial
and endothelial cell apoptosis/senescence which acceler-
ated lung injury in the early stage. However, cav-1 may
be beneficial in the late stage through anti-fibrosis [59].
MMPs are a family of zinc-dependent proteinases which
expressed by all cell types relevant to ARDS pathogen-
esis including alveolar epithelial cells, PMNs, macro-
phages, and fibroblasts. Many studies implicate MMPs
in the injurious process as well ALI/ARDS, which may
mainly contribute to its capability of degrading all com-
ponents of the extracellular matrix [60,61]. Vascular
endothelial growth factor (VEGF) and its receptors are
critical in the regulation of both vascular permeability
and endothelial cell survival. However, the role of VEGF
and related molecules in ALI/ARDS is controversial
[62]. PAI-1 is an endogenous inhibitor of the plasmino-
gen activators. Studies reported that elevated level of
PAI-1 is an independent risk factor for mortality and ad-
verse clinical outcomes for ALI patient [63]. RAGE is a
multi-ligand-binding receptor that can bind advanced
glycation end products, amyloid β-peptide, S100 pro-
teins, and high-mobility group box-1. RAGE-ligandTable 2 Examples of application for proteomics in the pathog
Protein technologies
caveolin-1, CD44, annexin A2,
protein S100-A10, or filamin A/B
Quantitative proteomic analysis
MMP-9
MMP-3, TIMP-1 liquid chromatography- electrospray
ionization mass spectrometry
VEGFR1, VEGFR2, NRP-1 Immunohistochemistry
PAI-1 ELISA
RAGE, PCPIII, BNP, ANG2, IL10,
TNF-[alpha], IL8
bead-based cytokine array, singleplex
enzyme-linked immunosorbent assay
AFT3 Microarray analysis, ELISA
HMW-HA:high-molecular-weight hyaluronan; CEM: caveolin-enriched microdomains;
VILI:ventilation-induced lung injury; BPD:bronchopulmonary dysplasia; GAPDH:glycer
factor; NRP-1:neuropilin-1; RAGE:receptor for advanced glycation end products; PCPI
IL-10:interleukin-10, TNF-alpha:tumor necrosis factor alpha; IL-8:interleukin-8.interaction results in intracellular signaling, which leads
to activation of the proinflammatory transcription factor
nuclear factor-κB (NF-κB) [64,65]. Study indicated
that RAGE may be useful as a biological marker of
alveolar type I cell injury [66]. TNF-alpha and IL-8 are
also well-validated inflammatory cytokines in ALI/ARDS
[57]. Figure 2 integrated these factors together to show
their potential roles in the pathogenesis of ALI/ARDS.
Metabolomics
Although the amplification of quantitative metabolomics
in clinic bioinformaticsis in its infancy, it has been in-
creasingly used recently. It is a unique tool of discovery
because it identifies multiple endogenous markers, and
it changes over time which can be predictive of clinical
outcome and therapeutic response [67,68]. The ability of
magnetic resonance imaging (MRI) and metabolic NMR
were investigated to detect and quantify inflammation-
mediated lung injury [69]. Recently, proton nuclear
magnetic resonance (1 H-NMR) based quantitative meta-
bolomics with subsequent computational analysis was
applied to investigate the plasma metabolic changes
associated with sepsis-induced ALI. Several metabolites
including glutathione, adenosine, phosphatidylserine, and
sphingomyelin were found different between patients
with ALI and healthy subjects. Additionally, computa-
tional network analysis was carried out to investigate a
distinct metabolic pathway for each metabolite [24].
Moreover, there is another case-control study conducted
on plasma samples from six albumin-treated and six
saline-treated patients to measure the metabolic changes
after albumin treatment. This study showed that bloodenisis of ALI in 2009-2010
Ref.
HMW-HA, via CD44-mediated CEM signaling events,
represents a potentially useful therapeutic agent for
LPS induced increasing of lung vascular permeability
[52]
Administration of doxycycline might be a significant
supportive therapeutic strategy in prevention of VILI.
[53]
MMPs in the BALF of premature neonates maybe
related to BPD development
[54]
VEGFR I and VEGFR2 were significant up-regulated
in early ARDS while Neuropilin-1 was down-regulated.
[55]
Higher PAI-1 levels are associated with increased
mortality and fewer ventilator-free days among
pediatric patients with ALI.
[56]
seven plasma biomarkers had a high diagnostic
accuracy in differentiating patients with trauma-
induced ALI
[57]
ATF3 may act to counterbalance CS and high volume
induced inflammation in Ventilator-induced Lung Injury
[58]
MMP:matrix metalloproteinase; TIMP:tissue inhibitors of metalloproteinases;
aldehyde-3-phosphate dehydrogenase; VEGF:vascular endothelial growth
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Figure 2 The potential mechanisms of these identified genes or proteins in the process of ALI/ARDS.
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with albumin treatment compared to saline treatment. In
this study, 1 H-NMR spectroscopy was introduced to
characterize systemic metabolic responses and identify
patients’ unique response to pharmacologic therapy and
appealed to play a potential role in the guiding treatment
and reducing healthcare cost [68].
In summary, ALI/ARDS is a complex disease which
can be initiated by a diverse array of precipitating factors
and involving the interplay of both the environment and
genetic factors. However, numerous environmental
agents can induce common pathological changes, in-
cluding damage to endothelial and epithelial cells, infil-
tration of inflammatory cells, cytokine release and so on.
Those common biological pathways may be controlling
generalized responses to injury and repair which cannot
distinguish the type of lung injury across different
models. On the other hand, susceptibility to ALI/ARDS
is also different among patients with same conditions.
Clinical models have identified risk factors and labora-
tory testing to evaluate severity, guide clinical therapy
and tell prognosis. However, these strategies remain
imprecise. The application of bioinformatics enables us
to identify the individual expression patterns as well as
the injury-specific pattern, thus may facilitate therapy
and predict prognosis. Besides, in the absence of signifi-
cant insights into disease pathogenesis, comprehensive
bioinformatics technologies may help us to get deep
understanding of such complex and life-threateningillness thus may provide novel therapeutic targets. Fi-
nally, there are several available samples that can be
used in the bioinformatics study of the lung, such as
exhaled breath gas, blood, lung tissue, pleural effusion
and BALF, which may largely facilitate the biomarker
research.
Conclusion
The genetic and proteomic approach to study ALI/
ARDS in clinical setting is still in an early stage, while
some important data have been generated. There is a
great need of further exploratory studies to better under-
stand the molecular mechanisms and pathophysiology
of ALI/ARDS. Much effort is also needed to validate
whether these biomarkers and drug targets are really
useful in early detection, prediction, and so are preven-
tion and treatment of lung diseases. The most important
issue to apply clinical bioinformation for target and bio-
marker identification and validation should to integrate
bioinformatics from genomics, proteomics and metabo-
lomics with clinical informatics and findings. We should
also think the value and role of clinical bioinformatics in
clinical research and study on ALI/ARDS to benefit per-
sonalized medicine and patient prognosis.
Different from other informatics, clinical bioinformat-
ics should focus more on clinical informatics, including
patient complaints, history, therapies, clinical symptoms
and signs, physician's examinations, biochemical analyses,
imaging profiles, pathologies and other measurements [70].
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scoring system to translate disease complexity of patient
information, clinical data, standard laboratory evaluations,
imaging data and symptoms into the digital [71]. This
particular study tried to combine clinical informatics with
protein profiles generated from antibody arrays to evaluate
the disease-specific, severity-associated, duration-related
biomarkers. Although the understanding of bioinformatics,
clinical bioinformatics, and clinical informatics remains
limited among clinicians, we believe clinical bioinformatics
will have a significant impact on critical care medicine
and public health. Since clinical bioinformatics is a
multidisciplinary field, which combined clinical informat-
ics, omics science, information technology, mathematics
and statistics together, we suggest the cooperation of
clinicians and technologists in this field. Progress in under-
standing of disease heterogeneity through the use of evolv-
ing biological, genomic, and genetic approaches should
provide major new insights into the pathogenesis and
treatment of ALI. Any effective and novel intervention
generated from clinical bioinformatics may prevent or im-
prove the high mortality and morbidity of ALI/ARDS.
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